TH166468B - Pharmaceutical form containing sodium. 1- (6- (morpholin-4-il) pyrimidin-4-il) -4- (1H-1,2,3-triazole-1-il) -1H - pyrazol-5-olet - Google Patents
Pharmaceutical form containing sodium. 1- (6- (morpholin-4-il) pyrimidin-4-il) -4- (1H-1,2,3-triazole-1-il) -1H - pyrazol-5-oletInfo
- Publication number
- TH166468B TH166468B TH1601002081A TH1601002081A TH166468B TH 166468 B TH166468 B TH 166468B TH 1601002081 A TH1601002081 A TH 1601002081A TH 1601002081 A TH1601002081 A TH 1601002081A TH 166468 B TH166468 B TH 166468B
- Authority
- TH
- Thailand
- Prior art keywords
- morpholin
- pyrazol
- pyrimidin
- triazole
- pharmaceutical form
- Prior art date
Links
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 title claims abstract 3
- 229910052708 sodium Inorganic materials 0.000 title claims abstract 3
- 239000011734 sodium Substances 0.000 title claims abstract 3
- 239000004480 active ingredient Substances 0.000 claims abstract 4
- 239000007787 solid Substances 0.000 claims abstract 2
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 claims 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 2
- 239000008101 lactose Substances 0.000 claims 2
- 150000001768 cations Chemical class 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 abstract 2
- 208000007502 Anemia Diseases 0.000 abstract 1
- 206010007554 Cardiac failure Diseases 0.000 abstract 1
- 208000008787 Cardiovascular Disease Diseases 0.000 abstract 1
- 206010019280 Heart failure Diseases 0.000 abstract 1
- 210000003734 Kidney Anatomy 0.000 abstract 1
- 206010062237 Renal impairment Diseases 0.000 abstract 1
- 230000001684 chronic Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drugs Drugs 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
Abstract
การประดิษฐ์นี้เกี่ยวข้องกับรูปแบบเภสัขภัณฑ์ที่เป็นของแข็งสำหรับให้ทางปาก ซึ่งประกอบ รวมด้วยโซเดียม 1-[6-(มอร์โฟลิน-4-อิล)ไพริมิดิน-4-อิล]-4-(1H-1,2,3-ไตรอะโซล-1-อิล)-1H- ไพราโซล-5-โอเลต (สารออกฤทธิ์ (I)) ซึ่งมีลักษณะเฉพาะโดยที่มีการปลดปล่อยสารออกฤทธิ์ (I) และ ยังเกี่ยวข้องกับวิธีการเตรียมรูปแบบเภสัชภัณฑ์ดังกล่าว, การใช้รูปแบบเภสัชภัณฑ์ดังกล่าวในฐานะ ตัวยา และการใช้รูปแบบเภสัชภัณฑ์ดังกล่าวสำหรับการป้องกัน, การป้องกันทุติยภูมิ หรือการรักษา ความผิดปกติ โดยเฉพาะความผิดปกติของหัวใจและหลอดเลือด, ภาวะหัวใจวาย, ภาวะเลือดจาง, ความผิดปกติเรื้อรังของไต และภาวะไตเสื่อมสมรรถภาพ The invention involved a solid oral form containing sodium. 1- (6- (morpholin-4-il) pyrimidin-4-il) -4- (1H-1,2,3-triazole-1-il) -1H - pyrazol-5-olate (active ingredient (I)), which is characterized by the release of active ingredient (I), and is also related to the method of preparing such pharmaceutical forms, the use of the pharmaceutical form. As a drug and its pharmaceutical form use for the prevention, secondary prevention or treatment of disorders, especially cardiovascular disorders, heart failure, anemia, dysfunction. Chronic kidney And renal impairment
Claims (1)
Publications (3)
| Publication Number | Publication Date |
|---|---|
| TH166468A TH166468A (en) | 2017-08-24 |
| TH166468B true TH166468B (en) | 2017-08-24 |
| TH1601002081A TH1601002081A (en) | 2017-08-24 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2017205536A3 (en) | Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer | |
| WO2015132799A3 (en) | Heterocyclic compounds | |
| WO2017123884A8 (en) | Heterocyclic compounds as rsv inhibitors | |
| MA40893A (en) | HYDROXYALKYL SUBSTITUTED PHENYLTRIAZOLE DERIVATIVES AND ASSOCIATED USES | |
| PH12018500610A1 (en) | Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity | |
| TN2016000268A1 (en) | N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2. | |
| EP4286372A3 (en) | Pyrimidinones as factor xia inhibitors | |
| WO2015120110A3 (en) | Novel pharmaceutical formulations | |
| MA53399B1 (en) | Substituted pyrazoles as inhibitors of human plasma kallikrein | |
| EA201991123A1 (en) | INDAZOLE DERIVATIVES AS ANTEGRIN ANTAGONISTS αV | |
| WO2018042362A9 (en) | Muscarinic m1 receptor positive allosteric modulators | |
| PH12019501811A1 (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| WO2016109217A3 (en) | Btk inhibitors | |
| EA201691674A1 (en) | 1,2-SUBSTITUTED CYCLOPENTANES AS ANTAGONISTS OF OREXIN RECEPTOR | |
| MX2019007117A (en) | Pharmaceutical combination comprising a t-type calcium channel blocker. | |
| PH12019500822A1 (en) | Crystalline forms of eravacycline | |
| MX2017013099A (en) | Methods for the treatment of inflammatory disorders. | |
| MX371102B (en) | New benzimidazole derivatives as antihistamine agents. | |
| SA519410097B1 (en) | Tetrahydroquinoline derivatives as p2x7 receptor antagonists | |
| SA518392325B1 (en) | Crystalline (2s,4r)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof | |
| EP3248603A4 (en) | Pharmaceutical composition for prevention, treatment or delay of alzheimer's disease or dementia containing g protein-coupled receptor 19 agent as active ingredient | |
| WO2016006975A3 (en) | Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof | |
| WO2016006974A3 (en) | Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof | |
| WO2015199418A3 (en) | Novel heterocyclic compound | |
| WO2015001541A3 (en) | Pharmaceutical film composition |